OpenAlex
PricingAboutJobs
Log inGet started
Work

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

HTML

Year: 2012
Type: article
Study design: Clinical Trial
Source: Blood
DOI: 10.1182/blood-2012-03-415307
Authors: Jorge Cortes, Jeff H. Lipton, Delphine Rea, Raghunadharao Digumarti, Charles Chuah, Nisha Nanda, Annie-Claude Benichou, Adam R. Craig, Mauricette Michallet, Franck E. Nicolini, Hagop Kantarjian
Institutions: The University of Texas MD Anderson Cancer Center, Princess Margaret Cancer Centre, Hôpital Saint-Louis, Recherche clinique appliquée à l'hématologie, Nizam's Institute of Medical Sciences, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, Hospices Civils de Lyon
Language: English

Topic: Chronic Myeloid Leukemia Treatments
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: omacetaxine mepesuccinate, chronic myeloid leukemia, T315I mutation, tyrosine kinase inhibitor resistance, protein synthesis inhibitors, subcutaneous administration, complete hematologic response, major cytogenetic response, progression-free survival, hematologic toxicity, chronic phase CML
SDG: Good health and well-being

Open Access status: green
OpenAlex ID: W2031892240
FWCI: 12.41
Cites: 28
Cited by: 145
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security